The contemporary psychiatric, neuropharmacological, and public health landscape across the United Kingdom, Germany, Sweden, New Zealand, Dubai, Australia, and the Netherlands is undergoing a profound structural evolution regarding classical consciousness-altering agents and rapid-acting psychoactive compounds. As clinical investigators, academic pharmacologists, and regulatory health authorities examine novel therapeutic models for treatment-resistant psychiatric conditions, distinguishing between distinct […]